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A b s t r a c t
Background: The evidence concerning the quality of secondary prevention of coronary artery disease (CAD) in Poland in 
recent years is scarce. 
Aim: To compare the implementation of secondary prevention guidelines into everyday clinical practice between 2006– 
–2007 and 2011–2012 in patients after hospitalisation due to CAD.
Methods: Five hospitals with departments of cardiology serving a city and its surrounding districts in the southern part of 
Poland participated in the study. Consecutive patients aged ≤ 80 years, hospitalised from April 1, 2005 to July 31, 2006 (first 
survey) and from April 1, 2010 to June 30, 2011 (second survey) due to acute coronary syndrome or for a myocardial revas-
cularisation procedure were recruited and interviewed 6–18 months after hospitalisation.
Results: Medical records of 640 patients were reviewed and included in the first survey and 466 in the second survey. The 
proportion of medical records with available information on smoking did not differ between the surveys, whereas the propor-
tion of medical records with available information on blood pressure and total cholesterol was lower in patients hospitalised 
in 2010–2011. The prescription rate of b-blockers at discharge decreased from 90% to 84% (p < 0.05), whereas the prescrip-
tion rates at discharge of other drug classes did not change significantly. The proportion of patients with high blood pressure  
(≥ 140/90 mm Hg) one year after hospitalisation decreased in 2011–2012 compared to 2006–2007 (from 48% to 35%, p < 0.05), 
whereas the proportion of subjects with high LDL cholesterol, high fasting glucose, and obesity did not change significantly. We 
did not note a significant difference in the smoking rate. The proportions of patients taking an antiplatelet agent (90% vs. 91%), 
a b-blocker (87% vs. 79%), an ACE inhibitor or a sartan (79% vs. 76%), a calcium antagonist (22% vs. 25%), a diuretic (35% 
vs. 45%), and a lipid-lowering drug (86% vs. 87%) one year after discharge did not change significantly (all p > 0.05). 
Conclusions: We noted a modest improvement in the implementation of CAD secondary prevention guidelines in everyday clini-
cal practice: blood pressure was better controlled, although the control of all other main risk factors did not change significantly. 
Our data provides evidence that there is a considerable potential for further reduction of cardiovascular risk in CAD patients.
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INTRODUCTION
Coronary artery disease (CAD) is the most common single 
cause of death in developed countries [1]. Likewise in 
Poland, cardiovascular (CV) diseases are the leading cause 
of mortality and morbidity. According to recent data, the 
standardised death rate from ischaemic heart disease in 
people under 65 years of age is 27.1 per 100,000. This ra-
tio is two times higher than in countries which were part of 
the old EU before enlargement in May 2004 [2]. In recent 
years, a rapid development of methods of treating CAD has 
been observed, both in terms of pharmacological as well as 
invasive methods. Nevertheless, the results of the mortality 
follow-up of European Action on Secondary Prevention 
through Intervention to Reduce Events (EUROASPIRE) 
I and II survey participants indicate that risk factors remain 
independent predictors of CV mortality in CAD patients [3]. 
The conclusion from another five year follow-up survey is 
that the provision of smoking cessation, advice on diet and 
optimal pharmacological treatment is likely to be crucial for 
reducing mortality in patients after myocardial infarction (MI) 
[4]. Thus, the highest priority for preventive cardiology was 
given to patients with established CAD [5].
The Cracovian Program for Secondary Prevention of 
Ischaemic Heart Disease was initiated in 1996 [6–8]. The 
main goal of the programme was to assess and improve the 
quality of medical care in the field of secondary prevention of 
CAD. The same centres took part in the EUROASPIRE surveys 
[9]. These initiatives allowed for the assessment of temporal 
changes in the implementation of recommendations as well 
as for international comparisons [9–11]. However, not much 
is known about changes in the implementation of secondary 
prevention guidelines in everyday clinical practice in Poland 
in recent years. 
Therefore, the aim of the present study was to compare 
the implementation of the guidelines concerning second-
ary prevention into everyday clinical practice between 
2005–2006 and 2011–2012, including the control of main 
risk factors and the cardioprotective medications prescription 
rates in patients after hospitalisation due to CAD.
MeThODs
Studied groups and the methods used in the Cracovian Pro-
gram for Secondary Prevention of Ischaemic Heart Disease 
have been described in earlier reports [10–12]. A brief de-
scription is given below.
Five hospitals having departments of cardiology in their 
structure, serving the area of Krakow (a city in the south of 
Poland) and surrounding districts participated in the study. 
The total population of this area was 1,200,000 inhabitants. In 
each department, medical records of consecutive patients 
hospitalised from April 1, 2005 to July 31, 2006 (first survey) 
and from April 1, 2010 to June 30, 2011 (second survey) due 
to acute MI (first or recurrent, no prior percutaneous coronary 
intervention [PCI] or coronary artery bypass grafting [CABG]), 
unstable angina (first or recurrent, no prior PCI or CABG), PCI 
(first, no prior CABG) or scheduled for CABG surgery (first) 
were reviewed and patients aged ≤ 80 years were identified 
retrospectively excluding those who died during their in-hos-
pital stay. If a patient was hospitalised more than once during 
the study period, only the first hospitalisation was regarded 
as an index event. Medical records of patients fulfilling the 
inclusion criteria were analysed using the standardised data 
collection form.  
Participants were invited to take part in a follow-up ex-
amination 6–18 months after discharge. Data on demographic 
characteristics, personal history of CAD, smoking status, blood 
pressure (BP), fasting glucose, plasma lipids, and prescribed 
medications were obtained using a standardised data collec-
tion form. Height  and weight were measured in a standing 
position without shoes and heavy outer garments using stand-
ard scales with a vertical ruler. Body mass index (BMI) was 
calculated according to the following formula: BMI = weight 
[kg]/(height [m])2. BP was measured twice, on the right upper 
arm in a sitting position after at least 5 min of rest. For plasma 
lipid and glucose measurements, a fasting venous blood sam-
ple was taken between 7.30 and 8.30 in the morning. For 
the present report, results of analyses which were done no 
later than 4 h after blood collection were used. Low density 
lipoprotein cholesterol (LDL-C) was calculated according to 
Friedewald’s formula. Diabetes mellitus was defined as fasting 
glucose level ≥ 7.0 mmol/L or taking antidiabetic treatment. 
We also calculated secondary prevention coefficient: for 
each risk factor (smoking, BP, LDL-C, glucose, BMI) controlled 
during the follow-up interview, one point was given. Addi-
tionally, one point was given for taking an antiplatelet agent, 
an angiotensin converting enzyme inhibitor (ACEI) or sartan, 
and a b-blocker in patients with MI in the history. Thus, the 
secondary prevention coefficient could vary from 1 to 8. The 
survey protocols were approved by the institutional Bioethics 
Committee. 
Statistical analysis
Categorical variables are reported as percentages and con-
tinuous variables as means ± standard deviation. We used 
general linear model as implemented in the STATISTICA 8.0 
software (StatSoft INC., Tulsa, OK, USA) for the assessment 
of changes in the studied variables over time. The differen-
ces are presented with their 95% confidence intervals. The 
secondary prevention coefficients were compared using 
Mann-Whitney-U test. A two-tailed p value of less than 0.05 
was regarded as indicating statistical significance. 
ResULTs
Medical records of 640 patients hospitalised in 2005– 
–2006 and 466 in 2010–2011 were reviewed and included 
into analyses. Mean age, sex and proportion of men and 
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Although we found no significant difference in the prescrip-
tion rate of ACEI and sartans (when analysed together), we 
noted a reduction in the use of ACEI (87.8% vs. 75.5%, 
adjusted p < 0.0001), whereas sartans became prescribed 
more frequently (1.1% vs. 12.0%, adjusted p < 0.0001). We 
found no significant difference in the prescription rate of 
lipid-lowering drugs (when all classes were analysed together). 
The prescription rates of statins (94.5% vs. 94.0%, adjusted 
p = NS) or fibrates (1.7% vs. 1.3%, adjusted p = NS) did not 
change significantly. 
The proportions of patients who did not reach the 
secondary prevention goals 6–18 months after discharge 
are presented in Table 4. Among all the studied risk fac-
women by survey are presented in Table 1. Participants of 
the second survey were older and more often were women. 
No significant difference in the index diagnosis distribution 
between surveys was found. 
Proportions of medical records with available information 
on risk factors are presented in Table 2. The proportion of 
medical records with available information on lipids and BP 
measurements decreased, whereas the proportion of medi-
cal records with information available on weight and height 
measurements increased significantly.
Cardioprotective drug prescription rates at discharge are 
shown in Table 3. Beta-blockers were prescribed less often 
and antinicotine drugs more often in the second survey. 
Table 1. Mean age, sex distribution, mean duration of education, mean period of time between index hospitalisation and follow-
-up examination, and index diagnosis distribution by survey
2005–2006 2010–2011 P 
Age [years] 61.1 ± 8.9 65.9 ± 9.9 < 0.05
Sex: men/women 71.1%/28.9% 60.7%/39.3% < 0.05
Mean duration of education* [years] 11.7 ± 3.5 12.0 ± 3.2 NS
Mean time between index hospitalisation and follow-up examination* [years] 1.11 ± 0.4 1.06 ± 0.2 NS
Index diagnosis:
Myocardial infarction
Unstable angina
Percutaneous coronary intervention
Coronary artery bypass graft
24.2%
27.5%
29.2%%
19.1%
27.7%
30.5%
25.1%
16.7%
NS
NS
NS
NS
*Among subjects who participated in the follow-up examination
Table 2. Temporal changes in proportions of hospital records with available information on measurement of risk factors during 
hospitalisation
Survey Smoking* BP** TC W & H
2005–2006 93.6% 98.9% 89.8% 70.9%
2010–2011 90.3% 97.4% 83.9% 84.6%
2010–2011 vs.
2005–2006***
–2.5%
(–5.8% to 0.8%)
–1.6%
(–3.2% to 0.0%)
–5.4%
(–9.5% to –1.3%)
16.2%
(11.2% to 21.1%)
*Any information on smoking in the medical record; **During first 24-h of hospitalisation; ***Differences adjusted for age, sex, and index diag-
nosis (95% confidence intervals); BP — blood pressure; TC — total cholesterol; W & H — weight and height
Table 3. Temporal changes in prescription rates of cardioprotective drugs at discharge
Survey AP BB ACEI/S CA D LLD AD AN
2005–2006 97.7% 89.7% 88.6% 21.6% 35.8% 95.6% 22.3% 0%
2010–2011 97.0% 84.3% 86.9% 27.5% 42.5% 94.4% 24.5% 0.6%
2010–2011 vs.
2005–2006*
–0.3%
(–2.3% to 
1.7%)
–4.2%
(–8.3% to 
–0.9%)
–2.0%
(–6.1% to 
2.0%)
1.5%
(–2.2% to 
8.2%)
1.4%
(–5.7% to 
6.0%)
–0.9% 
(–3.6% to 
1.8%)
–0.9% 
(–6.1% to 
4.3%)
0.8% 
(0.2% to 
1.4%)
*Differences adjusted for age, sex, and index diagnosis (95% confidence intervals); AP — antiplatelets; BB — beta-blockers; ACEI/S — angiotensin 
converting enzyme inhibitors/sartans; CA — calcium antagonists; D — diuretics; LLD — lipid lowering drugs; AD — antidiabetic agents; AN — 
antinicotine medications
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tors, only the control of BP was significantly improved in 
2011–2012 compared to 2006–2007. 
The proportion of patients taking antiplatelets, b-blockers, 
ACEI/sartans, calcium antagonists, diuretics, lipid-lowering 
drugs and antidiabetic agents did not differ significantly in 
2011–2012 compared to 2006–2007 (Table 5). We did not 
find any significant difference in the proportion of patients 
taking statins (84.2% vs. 86.4%, adjusted p = NS) nor fibrates 
(3.7% vs. 2.5%, adjusted p = NS). Although we found no sig-
nificant difference in the proportion of patients using ACEI or 
sartans (when analysed together), we noted a reduction in the 
use of ACEI (75.0% vs. 61.9%, adjusted p < 0.01), whereas 
sartans became used more frequently (5.1% vs. 14.4%, ad-
justed p < 0.0001).
Overall, 53.9% and 35.9% (adjusted p < 0.001) of sub-
jects participating in the first and second survey declared they 
had been advised to participate in a rehabilitation/secondary 
prevention programme following the index hospitalisation. 
The proportions of advised patients according to index diag-
nosis are presented in Figure 1. The proportion of patients 
who participated in the rehabilitation/secondary prevention 
programme following the index hospitalisation decreased 
from 47.1% to 33.3% (adjusted p < 0.01). Among advised 
patients, 86.5% and 91.6% (p = NS) participated in the re-
habilitation/secondary prevention programme. 
The proportions of smokers who were at any time in-
structed on methods of smoking cessation are presented in 
Table 6. Temporal changes in the proportion of patients who 
were at any time instructed on healthy diets are presented 
in Table 7. 
The mean secondary prevention coefficient in the group 
studied in 2006–2007 was 5.46 ± 1.27, and in 2011–2012 
it was 5.52 ± 1.33. The difference was not significant 
(adjusted p = 0.77). 
DIsCUssION
The evidence concerning the quality of CAD secondary 
prevention in Poland in recent years is rather scarce. In 
general, our results showed a modest improvement in the 
management of patients after hospitalisation due to CAD. 
The effectiveness of risk factor management improved only 
in the case of high BP. Proportions of active smokers and 
those with high LDL-C or high fasting glucose, as well as the 
proportion of obese patients, remained unchanged. Over 
70% of patients had an LDL-C level above the recommended 
goal in 2011–2012.
Based on the hospital records reviewed, one could 
assume that only smoking, hypercholesterolaemia, and 
hypertension were considered as important risk factors by 
the overwhelming majority of physicians in 2005–2006. The 
present analysis showed an improvement in the proportion 
of hospital records with available information on height 
and weight in 2010–2011 compared to 2005–2006. This 
phenomenon could be a sign of improved quality of medi-
cal care in patients hospitalised due to CAD; but another 
explanation could be that it is an effect of the formalisation 
Table 4. Temporal changes in proportions of patients who do not reach treatment goals 6–18 months after discharge
Survey Smoking BP ≥ 140/90  
mm Hg
LDL-C ≥ 2.5  
mmol/L
LDL-C ≥ 2.0  
mmol/L
LDL-C ≥ 1.8  
mmol/L
FG ≥ 7.0  
mmol/L
BMI ≥ 30  
kg/m2
2006–2007 19.7% 48.2% 39.5% 66.9% 78.4% 13.0% 33.0%
2011–2012 17.0% 35.4% 36.6% 61.9% 70.3% 12.4% 26.8%
2011–2012 vs.
2006–2007*
–3.6%
(–9.6% to 
2.5%)
–15.4%
(–23.6% to 
–7.3%)
–0.5%
(–8.8% to 
7.7%)
–2.3%
(–10.4% to 
5.9%)
–6.1%
(–13.4% to 
1.2%)
–1.5%
(–7.4% to 
4.3%)
–5.5% 
(–13.2% to 
2.1%)
*Differences adjusted for age, sex, index diagnosis, duration of education, and the period of time between index hospitalisation and examination  
(95% confidence intervals); BP — blood pressure; LDL-C — low density lipoprotein cholesterol; FG — fasting glucose; BMI — body mass index
Table 5. Temporal changes in proportion of patients taking cardioprotective drugs 6–18 months after discharge from the hospital
Survey AP BB ACEI/S CA D LLD AD AN*
2006–2007 90.0% 87.1% 79.0% 22.1% 34.5% 85.5% 21.8% 0.6%
2011–2012 91.1% 79.2% 76.0% 25.0% 45.3% 86.9% 23.3% 24.6%
2011–2012 vs.
2006–2007**
1.8%
(–2.9% to 
6.6%)
–5.3%
(–11.1% to 
0.5%)
–3.2%
(–10.1% to 
3.6%)
1.0%
(–7.8% to 
5.7%)
4.8%
(–2.9% to 
12.4%)
3.3% 
(–2.3% to 
8.9%)
–2.6% 
(–9.4% to 
4.2%)
24.5% 
(20.5% to 
28.6%)
*At any time from discharge to the follow-up interview 6–18 months after discharge; **Differences adjusted for age, sex, index diagnosis, du-
ration of education and the period of time between index hospitalisation and examination (95% confidence intervals); AP — antiplatelets; BB — 
beta-blockers; ACEI/S — angiotensin converting enzyme inhibitors/sartans; CA — calcium antagonists; D — diuretics; LLD — lipid lowering drugs; 
AD — antidiabetic agents; AN — antinicotine medications
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of hospital care which is ongoing in some Polish hospitals. In-
deed, some hospitals participating in the present study had 
started a programme of accreditation and quality assurance. 
Nevertheless, our present results suggest that nowadays most 
physicians note information about all main risk factors in the 
medical records.
Figure 1. Proportions of patients advised (as declared by the patients) to participate in a rehabilitation/secondary prevention 
programme following the index hospitalisation according to the index diagnosis. P values are adjusted for age, sex, duration of 
education and the period of time between index hospitalisation and the follow-up examination; CABG — coronary artery bypass 
grafting; MI — myocardial infarction; PCI — percutaneous coronary intervention; UA — unstable angina
Table 6. Temporal changes in proportion of smokers (before the index hospitalisation or at the time of the follow-up examina-
tion) being ever instructed by a physician on smoking cessation (as declared by the patients)
2006–2007 2011–2012 2011–2012 vs. 2006–2007*
Oral ad vice 90.1% 77.9% –11.4% (–21.5% to –12.6%)
Advice using printed materials 16.0% 44.6% 26.3% (13.1% to 39.4%)
Referral to a smoking cessation clinic 2.6% 3.8% 0.8% (–4.7% to 6.4%)
Nicotine replacement therapy 11.5% 7.6% –3.5% (–13.8% to 6.8%)
Bupropion or warenicline 3.2% 7.4% 4.3% (–2.4% to 10.9%)
Advice on other methods 3.2% 3.9% 0.7% (–5.3% to 6.8%)
*Differences adjusted for age, sex, index diagnosis, duration of education and the period of time between index hospitalisation and examination 
(95% confidence intervals)
Table 7. Temporal changes in proportion of patients being ever instructed by a physician on healthy diet (as declared by the 
patients)
2006–2007 2011–2012 2011–2012 vs. 2006–2007*
Reduction of salt intake 73.8% 85.0% 12.6% (5.8% to 19.4%)
Reduction of fat intake 86.9% 88.0% 2.3% (–3.2% to 7.8%)
Increase in unsaturated fats intake 84.9% 85.8% 2.4% (–3.4% to 8.3%)
Reduction of calories intake 66.9% 77.9% 12.8% (5.4% to 20.2%)
Increase in vegetables and fruits intake 84.6% 85.9% 2.1% (–3.8% to 8.0%)
Increase in fish intake 81.1% 78.2% 0.1% (–6.4% to 6.5%)
Increase in oily fish intake 53.7% 75.6% 24.1% (16.4% to 31.8%)
Reduction of sugar intake 71.9% 78.6% 5.7% (–13.7% to 12.8%)
Reduction of alcohol intake 50.4% 77.6% 28.7% (20.9% to 36.5%)
*Differences adjusted for age, sex, index diagnosis, duration of education and the period of time between index hospitalization and examination 
(95% confidence intervals)
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We found no major change in the proportion of smok-
ing subjects in the post-discharge period. It seems that the 
prevalence of smoking in patients after hospitalisation due to 
CAD has not changed for over 15 years [11]. Interestingly, sig-
nificantly more patients declared they had tried anti-tobacco 
medications in 2011–2012 than in 2006–2007. These findings 
could be explained by the less often oral advice provided by 
the physicians to smokers, and no increase in the propor-
tion of patients ever advised on anti-tobacco medications 
use. Probably, patients encouraged by advertising have tried 
over-the-counter anti-tobacco drugs more often. Indeed, it is 
well known that anti-tobacco medications (especially nicotine 
replacement therapy) are much less effective if their use is 
not supported by physicians [13]. Education on how to use 
these drugs is particularly important. Our present results can 
be seen as another proof of the need for high-quality educa-
tion provided by health professionals. 
In a previous report, we showed a significant improve-
ment in hypercholesterolaemia management between 
1997–1998 and 2006–2007 [11], but we found no sig-
nificant difference between 2006–2007 and 2011–2012 in 
the present analysis. It was shown that the most important 
factor influencing the control of hypercholesterolaemia in 
the post-discharge period is the in-hospital quality of hy-
percholesterolaemia management [14]. Indeed, we showed 
a gradual improvement in in-hospital hypercholesterolaemia 
management from 1996–1997 to 2005–2006 [10], but we did 
not find any significant difference in the proportion of medical 
records with available information on lipid measurements or 
any difference in the prescription rate at discharge of statins 
in the present study. 
We found control of hypercholesterolaemia much better 
when compared to high risk subgroup of the 3ST-POL study 
population [15]. However, important differences between the 
studies should be underlined. Śliż et al. [15] analysed ambula-
tory patients whereas we recruited subjects hospitalised due 
to CAD. Moreover, Śliż et al. [15] defined high risk patients 
as those who have CAD, diabetes or SCORE ≥ 5, whereas we 
analysed only coronary patients.
We noted virtually no change in the control of BP be-
tween 1997–1998 and 2006–2007 [11]. Interestingly, during 
subsequent years, the effectiveness of BP management has 
improved. Concerning the improvement in BP control, we 
can only speculate that the doses of antihypertensive drugs 
prescribed to CAD patients might have been increased in 
recent years. The improvement in the control of BP in coro-
nary patients has been accompanied by an improvement in 
BP control in the general Polish population as was shown in 
the recent NATPOL 2011 survey [16]. 
Although an insufficient proportion of patients (with the 
exception of patients after CABG) participated in a rehabilita-
tion programme in 2006–2007, we found even lower propor-
tions, especially among patients after PCI. In this regard, it 
should be underlined that all patients after CABG, PCI or acute 
coronary syndrome (ACS) should participate in a rehabilitation 
or secondary prevention programme [5]. 
Unfortunately, no study outside Krakow has been de-
signed specifically to assess secondary prevention of ischae-
mic heart disease in Polish hospitals and published in recent 
years. Data from several registries of patients hospitalised due 
to ACS has been published recently [17, 18]. In a nation-wide 
registry of ACS hospitalisations, it was estimated that the aver-
age prescription rate at discharge for aspirin is below 90%, 
for lipid-lowering drugs also < 90%, whereas b-blockers and 
ACEI it is below 80% [17]. In 3,564 patients hospitalised 
due to MI with ST-elevation in the Wielkopolska region, the 
prescription rates were 96% for antiplatelet agents, 74% for 
b-blockers, 58% for ACEI, and 90% for statins [18]. It should 
be underlined that the prescription rates of cardiopreventive 
medications in Poland are not lower compared to prescription 
rates in an average centre participating in the EUROASPIRE 
III survey [9], and are much higher compared to centres from 
high-income countries participating in the PURE study [19]. 
For example, the prescription rates of antiplatelets in British 
and German centres participating in the EUROASPIRE III 
survey were 94% and 91%, whereas the prescription rates 
of lipid-lowering drugs were 89% and 86%, respectively [9]. 
Taking all the above into account, it should be underlined 
that the control of all main risk factors was insufficient. In this 
regard, it is interesting to note the low proportion of CAD pa-
tients after hospitalisation due to CAD who had been advised 
to participate in a secondary prevention programme/cardiac 
rehabilitation. It has been shown that such programmes im-
prove prognosis [20, 21]. Indeed, it seems that a higher par-
ticipation rate in secondary prevention programmes/cardiac 
rehabilitation could result in better control of risk factors in 
this population. It should be also underlined that improved 
cooperation between hospital and outpatient clinic staff, as 
well as better access to a cardiologist in case of any suspicion 
of heart-related problems, could further improve the patients’ 
prognosis. Recently, experts from the Polish Cardiac Society 
described the ‘Optimal Model of Comprehensive Rehabili-
tation and Secondary Prevention’, wide implementation of 
which in Poland could be related to a decrease in deaths 
by 3,389, in MIs by 3,872, in myocardial revascularisation 
procedures by 13,499, and in cardiac hospitalisations by 
23,182 annually [22]. 
Limitations of the study
The present study has some limitations. Firstly, it is possible 
that some unrecognised differences in the subgroups served 
by particular hospitals or across diagnostic groups exist. These 
differences could influence the approach to secondary pre-
vention. Secondly, we were not able to assess the impact of 
changes in the implementation of secondary prevention on 
the risk of CV complications. Thirdly, our study participants 
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were not representative for all CAD patients. Participants were 
limited to those who had undergone an acute CAD event or 
revascularisation procedure. Therefore, our results should 
not be directly applied to other subjects. Finally, we did not 
analyse doses of cardioprotective drugs taken by patients. It 
is possible that BP, cholesterolaemia, and glycaemia were not 
controlled in some cases due to too small doses of prescribed 
drugs. We had no data on patient compliance. It is reasonable 
to suspect that some patients declared they took medications, 
but they might in reality take them irregularly.
CONCLUsIONs
We noted a modest improvement in the implementation of 
CAD secondary prevention guidelines in everyday clinical 
practice: BP was better controlled, although the control of all 
other main risk factors did not change significantly. Our data 
provides evidence that there is a considerable potential for 
a further reduction of CV risk in CAD patients.
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S t r e s z c z e n i e
Wstęp: Zgodnie z aktualnymi wytycznymi Europejskiego Towarzystwa Kardiologicznego za najważniejszą grupę docelową działań profilak-
tycznych uważa się osoby z chorobami układu sercowo-naczyniowego na podłożu miażdżycowym. Wyniki kilku opublikowanych badań 
wykazały, że realizacja wtórnej prewencji choroby niedokrwiennej serca (CAD) w codziennej praktyce lekarskiej jest niewystarczająca. 
Jednak aktualna sytuacja w Polsce w tym zakresie nie jest znana. 
Cel: Celem pracy było porównanie realizacji wtórnej prewencji CAD po wypisaniu ze szpitala w latach 2006–2007 i 2011–2012.
Metody: W badaniu uczestniczyło 5 krakowskich szpitali, w których strukturze znajduje się co najmniej jeden oddział kardiologii. Do 
badania kwalifikowano kolejnych pacjentów w wieku ≤ 80 lat, zamieszkałych na terenie byłego województwa krakowskiego, hospitalizo-
wanych od 1.04.2005 do 31.07.2006 (pierwsze badanie) oraz od 1.04.2010 do 30.06.2011 (drugie badanie) z powodu ostrego zespołu 
wieńcowego, w celu wykonania angioplastyki wieńcowej lub zakwalifikowanych do operacji pomostowania aortalno-wieńcowego. Na 
podstawie standaryzowanego kwestionariusza dokonano systematycznego przeglądu dokumentacji szpitalnej pacjentów zakwalifikowanych 
do badania. Nasilenie czynników ryzyka i stosowane leki oceniono 6–18 miesięcy po hospitalizacji.
Wyniki: Do analizy włączono dane 640 pacjentów hospitalizowanych w latach 2005–2006 oraz 466 osób w latach 2010–2011. Pacjenci 
leczeni w latach 2010–2011 byli starsi (66 ± 10 vs. 61 ± 9 lat). Odsetek historii chorób pacjentów zawierających informację o paleniu 
tytoniu (94% vs. 90%, p = NS) nie zmienił się istotnie, natomiast odsetek historii chorób zawierających informację o wartościach ciśnienia 
tętniczego (99% vs. 97%, p < 0,05) i stężenia cholesterolu całkowitego (90% vs. 84%, p < 0,05) był niższy w grupie hospitalizowanej 
w latach 2010–2011. Częstość zalecania b-adrenolityków przy wypisie ze szpitala zmniejszyła się (90% vs. 84%, p < 0,05), natomiast 
częstość zalecania przy wypisie leków przeciwpłytkowych (98% vs. 97%, p = NS), inhibitorów enzymu konwertującego angiotensynę 
(ACEI) lub sartanów (89% vs. 87%, p = NS), antagonistów wapnia (22% vs. 28%, p = NS), diuretyków (36% vs. 43%, p = NS) oraz 
leków hipolipemizujących (96% vs. 94%, p = NS) nie zmieniła się istotnie. Odsetek osób z podwyższonym ciśnieniem tętniczym  
(≥ 140/90 mm Hg) 6–18 miesięcy po hospitalizacji zmniejszył się w latach 2011–2012 w porównaniu z latami 2006–2007 (35% vs. 48%, 
p > 0,05). Natomiast częstość palenia tytoniu (20% w latach 2006–2007 vs. 17% w latach 2011–2012, p = NS), podwyższonego stężenia 
cholesterolu frakcji LDL (67% vs. 62%, p = NS), hiperglikemii (13% vs. 12%, p = NS) oraz otyłości (33% vs. 28%, p = NS) nie uległa zmia-
nie. Po 6–18 miesiącach po hospitalizacji nie stwierdzono istotnej zmiany pod względem częstości stosowania leków przeciwpłytkowych 
(90% vs. 91%, p = NS), b-adrenolityków (87% vs. 79%, p = NS), ACEI lub sartanów (79% vs. 76%, p = NS), antagonistów wapnia (22% 
vs. 25%, p = NS), diuretyków (35% vs. 45%, p = NS) oraz leków hipolipemizujących (86% vs. 87%, p = NS). 
Wnioski: Wyniki badania wskazują na poprawę kontroli ciśnienia tętniczego. Jednak częstość kontroli pozostałych głównych czynników 
ryzyka i częstość stosowania leków poprawiających rokowanie u osób z CAD nie uległa zmianie. Wyniki badania wskazują na możliwość 
poprawy rokowania pacjentów po hospitalizacji z powodu CAD poprzez polepszenie realizacji zasad wtórnej prewencji w codziennej 
praktyce lekarskiej. 
Słowa kluczowe: choroba niedokrwienna serca, czynniki ryzyka, wtórna prewencja
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